NO | ထုတ်ကုန်များ | CAs No | အဓိကအရည်အသွေးအညွှန်းကိန်း | |||
သန့်ရှင်းြရဲ | မက်စ်။ ညစ်ညူးခြင်း | စုစုပေါင်းအရည်ပျော်ပစ္စည်းအကြွင်းအကျန် | စိုထိုင်းဆ | |||
1 | fmoc-β-Ala-Ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
2 | fmoc-d-Ala-D-Ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
3 | fmoc-β-Ala-D-Ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
4 | FMOC-arg (PBF) -argarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
5 | FMOC-β-Ala-arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
6 | fmoc-d-arg (PBF) -D-arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
7 | FMOC-β-Ala-D-arg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
8 | FMOC-Homoarg (PBF) -homoarg (PBF) -homoargharge | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
9 | FMOC-β-Ala-Ala-Homoarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
10 | fmoc-asn (trt) -asn (trt) -aoh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
11 | fmoc-β-Ala-Asn (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
12 | FMOC-ASP (OTBU) -asp (OTBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
13 | FMOC-β-Ala-Asp (OTBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
14 | fmoc-cys (trt) -cys (trt) -cys | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
15 | fmoc-β-Ala-cys (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
16 | fmoc-cys (ACM) -Cy (ACM) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
17 | fmoc-β-Ala-cys (ACM) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
18 | FMOC-GLN (TRIT) -GLN (TRT) -loh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
19 | FMOC-β-Ala-GLN (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
20 | FMOC-Glu (OTBU) -Glu (OTBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
21 | fmoc-β -la-glu (otbu) -oh.h2o | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
22 | FMOC-β-Ala-gly-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
23 | fmoc-န်းမာ (TRT) -His (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
24 | FMOC-β-Ala-all (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
25 | fmoc-file-iile-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
26 | FMOC-β-Ala-fil-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
27 | fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
28 | fmoc-β-ala-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
29 | fmoc-d-leu-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
30 | fmoc-β-ala-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
31 | FMOC-LYS (BOC) -lys (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
32 | fmoc-β-ala-lys (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
33 | FMOC-LYS (Alloc) -lys (Alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
34 | fmoc-β-ala-lys (alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
35 | fmoc-met-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
36 | fmoc-β -la-met-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
37 | FMOC-Orn (BOC) -orn (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
38 | fmoc-β-ala-orn (boc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
39 | fmoc-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
40 | fmoc-β-ala-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
41 | fmoc-d-phe-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
42 | fmoc-β-ala-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
43 | FMOC-Pro-Pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
44 | fmoc-β-Ala-Pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
45 | FMOC-SER (TBU) -ser (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
46 | FMOC-β-Ala-SER (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
47 | FMOC-SER (TRT) -ser (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
48 | fmoc-β -la-ser (trt) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
49 | FMOC-THR (TBU) - | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
50 | fmoc-β-ala-ther (Tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
51 | FMOC-TRP (BOC) -trp (BOC) -troh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
52 | fmoc-β-Ala-trp (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
53 | FMOC-D-TRP (BOC) -D-trp (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
54 | FMOC-β-Ala-D-TRP (BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
55 | FMOC-Tyr (Tbu) -tyr (TBU) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
56 | FMOC-β-Ala-Tyr (Tbu) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
57 | fmoc-d-tyr (et) -D-Tyr (ET) -eoh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
58 | fmoc-β-ala-d-tyr (et) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
59 | fmoc-tyr (ငါ့ကို) -tyr (ငါ့ကို) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
60 | FMOC-β-Ala-Tyr (Meoh) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
61 | fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
62 | fmoc-β-ala-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
63 | fmoc-d-cit-cit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
64 | fmoc-β-Ala-D-Cit-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
65 | fmoc-β-ala-dab-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
66 | fmoc- (3- (2-naphthyl) -D-Ala) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
67 | FMOC-β-Ala-3- (2-naphthyl) -D-Ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
68 | fmoc- (3- (3 pyridyll) -D-Ala) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
69 | FMOC-β-Ala-3- (3 pyridyll) -D-Ala-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
70 | fmoc- (4-chloro-d-phe) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
71 | fmoc-β-ala-4-4-chloro-d-D-Phe- အိုး | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
72 | fmoc- (D-4 (tbucbm)) 2-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
73 | fmoc-β-ala-d-4 (tbucbm) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
74 | fmoc-aph (l-hor) - သပ် (L-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
75 | fmoc-β-ala-aph (l-hor) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
76 | FMOC-LYS (IPR, BOC) -lys (IPR, BOC) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
77 | fmoc-β-ala-lys (IPR, BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
78 | fmoc-β-Ala-Aeea-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
79 | fmoc-aib-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
80 | fmoc-β-ala-aib-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
81 | fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
82 | H-arg (PBF) -oh | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
83 | fmoc-d-arg-oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
84 | HD-arg (PBF) -oh | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
85 | fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
86 | H-homoarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
87 | fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
88 | HD-homoarg (PBF) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
89 | fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
90 | H-Asn (TRT) -oh | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
91 | fmoc-asp-oh | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
92 | H-Asp (OTBU) -oh | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
93 | fmoc-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
94 | H-gys (trt) -oh | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
95 | H-cys (ACM) -oh.hcl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
96 | fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
97 | H-GLN (TRT) -oh | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
98 | fmoc-glu-oh | 121333-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
99 | H-Glu (OTBU) -oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
100 | fmoc-he he | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
101 | H-TRY (TRT) -oh | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
102 | BOC-hem | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
103 | fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
104 | H-Lys (BOC) -oh | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
105 | H-Lys (Alloc) -oh | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
106 | FMOC-ORN-OH.HCL | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
107 | H-Orn (BOC) -oh | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
108 | fmoc-ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
109 | H-SER (TBU) -oh | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
110 | H-SER (TRT) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
111 | fmoc-thr.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
112 | H-THR (TBU) -oh | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
113 | fmoc-trp-oh | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
114 | H-TRP (BOC) -oh | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
115 | fmoc-d-trp-oh | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
116 | HD-TRP (BOC) -oh | 201290-11-1-11 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
117 | fmoc-tyr-oh | 92954-90-0-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
118 | H-Tyr (Tbu) -oh | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
119 | fmoc-d-tyr-oh | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
120 | HD-Tyr (ET) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
121 | H-Tyr (Me) -oh.hcl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
122 | FMOC-D-4 (CBM) -oh | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
123 | HD-4 (TBUCBM) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
124 | FMOC-LYS (IPR) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
125 | H-Lys (IPR, BOC) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
လေျာ်ခြင်း
Gentleex သည်အရည်အသွေးကောင်းသည့်ထုတ်ကုန်များကိုပေးသည်, အကယ်. ကုန်ပစ္စည်းအရည်အသွေးကို 0 န်ဆောင်မှုခံယူသူမှ 0 န်ဆောင်မှုခံယူသူမှ 0 န်ဆောင်မှုခံယူသူအားလုံလောက်သောအထောက်အထားများဖြင့် 0 န်ဆောင်မှုခံယူရန်လိုအပ်ပါကကျွန်ုပ်တို့သည်လိုအပ်သောအကဲဖြတ်ခြင်းနှင့်အကဲဖြတ်ခြင်းများကိုပေးလိမ့်မည်။
ထုတ်ဖေါ်ခြင်း
ဆေးဝါးထုတ်ကုန်များရရှိသည့်ဆေးဝါးများသည်တန်ချိန်စံချိန်တင်ရရှိသည်, ဓာတုပစ္စည်းများ၏စွမ်းဆောင်ရည်သည် 100tons + တန်းသို့ရောက်ရှိသည်။
သုတေသနနှင့်ဖွံ့ဖြိုးတိုးတက်မှု
နှစ်စဉ် R & D အဖွဲ့မှတပ်ဆင်ထားသည့်ထုတ်ကုန်အသစ်များတည်ဆောက်ရန်အစီအစဉ်များကိုတည်ဆောက်ရန်အစီအစဉ်ရှိသည်, ရည်မှန်းချက်များချမှတ်သောအခါအဖွဲ့ 0 င်တိုင်းသည် KPI တာဝန်ယူမှုနှင့်မက်လုံးပေးမူဝါဒများနှင့်ဆက်လက်လုပ်ဆောင်ရန်လိုအပ်လိမ့်မည်။